Transforming obesity: The advancement of multi-receptor drugs

In the paper

“Subsequent studies entailed the generation of a fatty-acylated version of the peptide with balanced potent activity selective to only GLP-1R and GIPR124,125.”

What the sources say

• ?Not checked — no full text of the sourcecites [124] source
• Disputed

  The Synthesis section describes a palmitic-acid modification, so the fatty-acylated part is supported. But the Results section identifies MEDI0382 as a GLP-1/glucagon receptor agonist and reports more than 10,000-fold selectivity over the GIP receptor—the opposite of the claimed GLP-1R/GIPR activity. (LLM, conf=0.94)

  Checked by a reasoning model — may be wrong.

  cites [125] sourceExperimental — accuracy not yet measured

In the paper

“In subjects with obesity without T2D, 26 weeks of treatment with JNJ-64565111, at the highest tested dose of 10 mg, resulted in a placebo-corrected weight loss of ~10%, relative to −5.8% in liraglutide-treated controls101.”

What the sources say

• Disputed

  The Abstract describes a 68-week trial of 2.4-mg semaglutide versus placebo in adults without diabetes, not a 26-week trial of 10-mg JNJ-64565111. The Discussion reports a 12.4% placebo-corrected reduction for semaglutide and cites 4.5% for liraglutide in a separate trial; it does not report liraglutide-treated controls with −5.8% weight loss. Page numbers were not provided in our copy. (LLM, conf=0.89)

  Checked by a reasoning model — may be wrong.

  cites [101] sourceExperimental — accuracy not yet measured

In the paper

“certain GIPR antagonists reduce body weight and caloric intake in diet-induced obese mice and non-human primates, particularly when given in adjunct to GLP-1R agonism112,113.”

What the sources say

• ?Not checked — no full text of the sourcecites [112] source
• Disputed

  The Results and Discussion (page unavailable) attribute reduced body weight and total energy intake in obese mice and monkeys to dual GLP-1R/GCGR agonists. The cited study did not test GIPR antagonists or their use alongside GLP-1R agonists; it identifies a different receptor and an agonist, rather than an antagonist, as the treatment. (LLM, conf=0.86)

  Checked by a reasoning model — may be wrong.

  cites [113] sourceExperimental — accuracy not yet measured

In the paper

“Finally, in a Phase 2 substudy in subjects with MASLD, retatrutide significantly decreased liver fat; displaying a substantial reduction of up to 86% over a 48 week period167 (Table 2),”

What the sources say

• Disputed

  The trial description identifies this as a phase 3b study of tirzepatide versus insulin lispro in adults with type 2 diabetes, with outcomes assessed at week 52—not a phase 2 retatrutide substudy in people with MASLD. The Discussion mentions liver-fat reduction only as a reported effect of tirzepatide from another study; it does not report an 86% reduction over 48 weeks. (LLM, conf=0.89)

  Checked by a reasoning model — may be wrong.

  cites [167] sourceExperimental — accuracy not yet measured

In the paper

“In a back-to-back published Phase 2 study comprising of subjects with obesity and T2D, 36 weeks of retatrutide treatment reduced body weight by ~16.9%, compared to ~2% or ~3% with dulaglutide or placebo, respectively;”

What the sources say

• Disputed

  The Abstract (page not provided) identifies this as a phase 3 trial of tirzepatide versus placebo added to insulin glargine over 40 weeks, not a 36-week phase 2 retatrutide trial with a dulaglutide comparator. Its reported weight changes are −5.4 to −8.8 kg with tirzepatide and +1.6 kg with placebo, not the percentages attributed in the claim. (LLM, conf=0.90)

  Checked by a reasoning model — may be wrong.

  cites [166] sourceExperimental — accuracy not yet measured

In the paper

“A recent study utilizing a GIPR-blocking antibody conjugated with a potent GLP-1R agonist in obese subjects, has reignited interest in such multi-mode therapy174.”

What the sources say

• Disputed

  The Main section identifies tirzepatide as an agonist of both GIPR and GLP-1R, not a GIPR-blocking antibody conjugated to a GLP-1R agonist. It reports experiments on isolated human islets, not a study administering that conjugate to obese subjects. Page numbers are not supplied in our copy. (LLM, conf=0.89)

  Checked by a reasoning model — may be wrong.

  cites [174] sourceExperimental — accuracy not yet measured

In the paper

“The regulation of body weight is orchestrated primarily by the brain and adipose tissue (Figure 1), which constantly integrate information related to the body’s energetic state to adjust food intake, satiety and energy balance8,10.”

What the sources say

• Partly supported

  The Introduction describes constant signal integration between brain feeding centres and the periphery to regulate hunger and satiety. It identifies adipose tissue as one source of signals, alongside the gastrointestinal tract, liver and pancreas; it does not identify adipose tissue as a primary coordinator or say that adipose tissue itself integrates energy-state information. (LLM, conf=0.83)

  cites [8] sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [10] source

In the paper

“In fact, studies have shown that the inhibition of glucagon secretion by GLP-1, is equally as important as enhanced insulin secretion in controlling glucose levels in T2D54.”

What the sources say

• Partly supported

  The discussion on p. E1052 reports earlier findings that GLP-1 inhibits glucagon release in rats, and this paper measures insulin and glucagon after a glucose meal in rats. It does not establish that glucagon suppression is equally important as insulin secretion for glucose control in people with T2D; its own glucagon results do not demonstrate that comparison. (LLM, conf=0.85)

  cites [54] sourceExperimental — accuracy not yet measured

In the paper

“The more recently developed SAR425899 employs elements of glucagon in the sequence of exendin-4, to provide GCGR agonism while maintaining GLP-1R activation82.”

What the sources say

• ?Could not verify

  The Results passage discusses a GLP-1/GIP dual agonist, while the key resources table lists GLP-1 and GIP compounds; neither addresses SAR425899. Searches for SAR425899, exendin-4, and glucagon elements found no passage describing the claimed peptide design or GCGR activity (page numbers unavailable). (LLM, conf=0.76)

  cites [82] sourceExperimental — accuracy not yet measured

In the paper

“The first preclinically evaluated GLP-1R/GCGR co-agonist was based on the glucagon sequence, in which amino acid residues from GLP-1 and GIP were stepwise introduced to achieve balanced activity at both target receptors79.”

What the sources say

• ?Could not verify

  The Introduction (page unavailable) discusses GIPR/GLP-1R co-agonism, and the Results (page unavailable) describe GIPR-specific peptide probes. Neither passage addresses the first preclinical GLP-1R/GCGR co-agonist or stepwise addition of GLP-1 and GIP residues to a glucagon sequence; searches for those design details found no supporting passage. (LLM, conf=0.76)

  cites [79] sourceExperimental — accuracy not yet measured

In the paper

“Consistent with this model is a battery of preclinical and clinical studies demonstrating that weight loss induced by GLP-1R agonism is enhanced when adjunctively administered with glucagon, GIP, amylin, CCK or FGF21, which can be achieved as co-therapy, or in a unimolecular polyagonist formulation8.”

What the sources say

• Partly supported

  The Incretin-based therapy section (page unavailable) reports enhanced performance for GLP-1 co-agonists with GIP or glucagon and lists exenatide with CCK as a preclinical co-therapy. It does not establish enhanced weight loss for every listed combination: the Outlook section (page unavailable) poses GLP-1 with amylin or FGF21 as a question for future study, and the CCK example is not accompanied by an explicit comparison showing enhancement. (LLM, conf=0.88)

  cites [8] sourceExperimental — accuracy not yet measured

In the paper

“Furthermore, GLP-1 exerts a significant effect on body weight, by inhibiting food intake through centrally mediated mechanisms8.”

What the sources say

• Supported

  The Introduction states that GLP1 decreases food intake through CNS mechanisms. The Incretin-based therapy section also reports weight-lowering effects of GLP1 receptor agonism, supporting the cited sentence's body-weight claim. (LLM, conf=0.93)

  cites [8] source

In the paper

“GIP-driven weight loss is also synergistically enhanced by adjunct GLP-1R agonism47-49,117.”

What the sources say

• ?Not checked — no full text of the sourcecites [47] source
• ?Not checked — no full text of the sourcecites [48] source
• ?Not checked — no full text of the sourcecites [49] source
• ?Could not verify

  The Introduction and Discussion describe GLP-1/glucagon co-agonism, not GLP-1/GIP co-agonism. The Results > Body weight report weight loss but do not test whether adding GLP-1R agonism synergistically enhances GIP-driven weight loss. Searches for GIP and synergistic weight loss found no passage addressing that claim; page numbers were not available in our copy. (LLM, conf=0.76)

  cites [117] sourceExperimental — accuracy not yet measured

In the paper

“pharmacological or genetic inhibition of the GIPR has been shown to alleviate intramuscular lipid accumulation in aged mice108.”

What the sources say

• ?Could not verify

  The paper’s section on kidney-specific Gcgr-null mice reports increased lipid deposition in the kidney, not reduced lipid accumulation in muscle. The methods describe mice generally aged 3–5 months. Searches for GIPR inhibition and intramuscular lipid accumulation in aged mice found no passage addressing the claim; the indexed passages provide no page numbers. (LLM, conf=0.77)

  cites [108] sourceExperimental — accuracy not yet measured

In the paper

“some GIPR mutations are associated with a lower body mass index in humans109-111”

What the sources say

• ?Could not verify

  The GLP-1/GIP coagonism section discusses GIP receptor ablation and body-weight gain in mice, but does not report an association between GIPR mutations and lower BMI in humans. Searches for GIPR mutations, genetic variants, and polymorphisms did not locate that claim in our copy; page numbers were unavailable. (LLM, conf=0.75)

  cites [109] sourceExperimental — accuracy not yet measured
• ?Could not verify

  The discussion of glucagon-receptor knockout mice in “Glucagon Stimulates Hepatic Beta-Oxidation and Inhibits Lipogenesis” addresses body composition, but not human GIPR mutations or BMI. Searches for GIPR and glucose-dependent insulinotropic polypeptide receptor variants found no passage in our copy reporting the claimed association. (LLM, conf=0.74)

  cites [110] sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [111] source

In the paper

“germline Gipr-deficient mice are protected from diet-induced obesity103”

What the sources say

• ?Could not verify

  The passages in Section 5 discuss glucagon receptor (GcgR) signaling and obesity in mice, not germline deficiency of the GIP receptor (Gipr). Searches for Gipr-deficient mice and GIP receptor knockout with diet-induced obesity found no passage addressing the claim in our copy. (LLM, conf=0.75)

  cites [103] sourceExperimental — accuracy not yet measured

In the paper

“In both studies, treatment with JNJ-64565111 resulted in an increased appearance of adverse effects, most notably nausea and vomiting101,102.”

What the sources say

• ?Could not verify

  Table 3 (p. 1000) and the Safety and Side-Effect Profile report more nausea and vomiting with semaglutide than with placebo in this trial. A search for JNJ-64565111 found no passage about that treatment, and the cited paper does not report the claimed result in both studies. (LLM, conf=0.78)

  cites [101] sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [102] source

In the paper

“protection from obesity is also observed in Glp1r-deficient mice114,115”

What the sources say

• Supported

  The Results section, under “Metabolic effects of DualAG and GLPAG in Glp1r−/− and Gcgr−/− mice,” explicitly says that both receptor-knockout mouse lines are resistant to diet-induced obesity. This supports the claim for Glp1r-deficient mice, with the qualification that the reported resistance is to diet-induced obesity. (LLM, conf=0.93)

  cites [114] source
• ?Not checked — no full text of the sourcecites [115] source

In the paper

“treatment of brain-specific Glp1r-deficient mice with a GLP-1R/GIPR co-agonist retains anti-inflammatory action”

What the sources say

• ?Could not verify

  The Introduction discusses dual GLP-1R/glucagon-receptor agonists, and the Conclusion reports metabolic effects of SAR425899. Searches for brain-specific Glp1r-deficient mice, GLP-1R/GIPR co-agonism, and anti-inflammatory effects found no passage addressing the claimed mouse experiment. No page numbers were available in our copy. (LLM, conf=0.76)

  cites [118] sourceExperimental — accuracy not yet measured

In the paper

“the anti-inflammatory effects of GLP-1R activation are mediated exclusively through the central actions of GLP-1R118.”

What the sources say

• ?Could not verify

  The Introduction discusses GLP-1R effects on food intake and metabolism, while the Discussion and Conclusion address metabolic adaptation and fat oxidation. Searches for anti-inflammatory effects and central or brain-mediated GLP-1R action found no passage addressing whether inflammation is reduced, let alone whether that effect occurs exclusively through the brain. No page numbers are available in our copy. (LLM, conf=0.77)

  cites [118] sourceExperimental — accuracy not yet measured

In the paper

“In obese subjects, NN9277 displayed impressive weight loss efficacy, with a placebo-adjusted reduction in body weight of ~12.6% following 12 weeks of treatment99.”

What the sources say

• ?Could not verify

  The retrieved passages do not mention NN9277 or report a 12-week, placebo-adjusted weight reduction for it. Section 2.4 instead reports weight-loss results for semaglutide after 68 weeks; searches for NN9277 and the 12.6% figure did not locate the claimed result in our copy. (LLM, conf=0.74)

  cites [99] sourceExperimental — accuracy not yet measured

In the paper

“suggesting that peripheral GIPR activity in adipose tissue and immune cells, i.e. macrophages, can elicit positive systemic effects118.”

What the sources say

• ?Could not verify

  The Introduction and Discussion address dual GLP-1R/GCGR agonism and its metabolic effects, not GIPR activity. Searches for GIPR, peripheral adipose tissue, and macrophages found no passage addressing the claimed effects; the cited paper’s findings therefore do not verify this attribution. The available passages have no page numbers. (LLM, conf=0.76)

  cites [118] sourceExperimental — accuracy not yet measured

In the paper

“GIPR agonist treatment is equally effective in promoting weight loss in obese mice”

What the sources say

• ?Not checked — no full text of the sourcecites [47] source
• ?Not checked — no full text of the sourcecites [48] source
• ?Not checked — no full text of the sourcecites [49] source
• ?Could not verify

  The Results (Body weight; page unavailable) report weight loss in overweight or obese patients with type 2 diabetes treated with SAR425899 or liraglutide. The paper describes SAR425899 as a GLP-1/glucagon receptor agonist, not a GIPR agonist. Searches for GIPR treatment and obese mice found no passage addressing the claim. (LLM, conf=0.77)

  cites [117] sourceExperimental — accuracy not yet measured

In the paper

“Similarly, in a study with comparable treatment duration, albeit in subjects with obesity and T2D, tirzepatide reduced body weight by −14.7%, relative to −3.2% in placebo controls143.”

What the sources say

• ?Could not verify

  The Results sections discuss genetic loci associated with BMI and the possible role of GIPR in weight regulation; no passage reports a tirzepatide treatment study. Searches for tirzepatide, placebo, and the 14.7% and 3.2% weight-loss figures found no matching result in our copy. Page numbers were not available. (LLM, conf=0.78)

  cites [143] sourceExperimental — accuracy not yet measured

In the paper

“After 1 year of treatment, weight loss of ≥10% was achieved in 62.1% of subjects receiving tirzepatide, and in 38.0% of subjects receiving semaglutide149.”

What the sources say

• ?Could not verify

  The Methods describe a study of eight patients with type 2 diabetes, and the Insulin treatment section reports outcomes after four weeks. Searches for tirzepatide, semaglutide, the stated percentages, and a one-year meta-analysis found no passage addressing the claimed weight-loss results. Page numbers were not available in our copy. (LLM, conf=0.78)

  cites [149] sourceExperimental — accuracy not yet measured

In the paper

“studies in musk shrews and mice revealed that GIPR mono-agonist administration attenuated the emetic effect of GLP-1R agonism44,131”

What the sources say

• ?Could not verify

  The Abstract and Discussion describe GIP removal from rat gut extracts and its effect on glucose-induced insulin release; neither addresses emesis. Searches for musk shrews, mice, nausea or vomiting, and GIPR and GLP-1R agonism found no passage supporting the attributed finding. Page numbers were not available in our copy. (LLM, conf=0.78)

  cites [44] sourceExperimental — accuracy not yet measured
• ?Could not verify

  The Results > Safety and tolerability section reports nausea and vomiting in patients receiving cotadutide, a GLP-1/glucagon receptor agonist. Searches for musk shrews, mice, and GIPR mono-agonism found no passage about whether a GIPR agonist reduces GLP-1R-induced emesis. Page numbers were not available in our copy. (LLM, conf=0.76)

  cites [131] sourceExperimental — accuracy not yet measured

In the paper

“Despite the slight differences based on the subject cohort and the duration of treatment, this magnitude of weight loss was largely consistent with the SURPASS trials132-140.”

What the sources say

• Partly supported

  The Introduction (page unavailable) reports that tirzepatide has demonstrated mean weight loss of up to 19%. The paper does not say that this magnitude was consistent with the SURPASS trials despite differences in populations or treatment duration; its own trials studied NN1177. (LLM, conf=0.81)

  cites [132] sourceExperimental — accuracy not yet measured
• ?Could not verify

  The Results report weight loss with ALT-801 in mice, while the Introduction discusses a broad range of weight loss with clinical GLP-1-based treatments. Although the References list a tirzepatide trial, no passage compares a tirzepatide weight-loss magnitude with the SURPASS trials. Searches for “SURPASS” and “tirzepatide” did not establish the claimed consistency. (LLM, conf=0.76)

  cites [133] sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [134] source
• ?Not checked — no full text of the sourcecites [135] source
• ?Not checked — no full text of the sourcecites [136] source
• ?Could not verify

  The Methods and Results describe short infusions of GIP and GLP-1 [7-36 amide] and measure insulin-related responses, not weight loss. Searches for tirzepatide, SURPASS trials, and weight-loss outcomes found no passage in our copy addressing the claimed comparison. (LLM, conf=0.79)

  cites [137] sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [138] source
• ?Not checked — no full text of the sourcecites [139] source
• ?Could not verify

  The Results section ('LA-Agonist has the same effect on body weight as muGIPR-Ab'; page unavailable) reports weight changes in mice treated with a GIPR agonist, an antibody, and/or liraglutide. Searches for tirzepatide and SURPASS found no passage comparing tirzepatide weight loss with those trials, so our copy does not address the attributed comparison. (LLM, conf=0.78)

  cites [140] sourceExperimental — accuracy not yet measured

In the paper

“The peptide was further shown to induce a switch of macronutrient intake by selectively dampening palatable high-fat/sweet-taste preference to a low-fat chow diet preference130.”

What the sources say

• ?Could not verify

  The Introduction identifies the studied peptide as cotadutide, and the Study End Points section lists metabolic, hepatic, lipid, and safety measures—not food preference. Searches for tirzepatide, high-fat/sweet-taste preference, and low-fat chow found no passage addressing the claimed dietary switch. (LLM, conf=0.78)

  cites [130] sourceExperimental — accuracy not yet measured

In the paper

“In the SURMOUNT-1 trial for obese subjects without T2D, 72 weeks of tirzepatide treatment achieved weight loss of up to −20.9%, relative to placebo controls142.”

What the sources say

• ?Could not verify

  The Discussion discusses weight loss with combined GIPR and GLP-1R activation, but does not report SURMOUNT-1 results. Searches for SURMOUNT-1, tirzepatide, 72 weeks, and 20.9% found no passage in our copy supporting the trial-specific claim. (LLM, conf=0.78)

  cites [142] sourceExperimental — accuracy not yet measured

In the paper

“In the SURMOUNT-3 trial, the effects of tirzepatide were assessed in obese subjects without T2D that underwent intensive lifestyle modifications; the supplemental therapeutic treatment with tirzepatide for 72 weeks reduced body weight by −18.4%, relative to a 2.5% weight gain evident in placebo controls144.”

What the sources say

• ?Could not verify

  The Methods section describes genotyping and obesity-association studies, not a treatment trial. Searches of our copy for SURMOUNT-3, tirzepatide, the 72-week duration, and the reported weight changes found no passage addressing the claim; the Background discusses different interventions. (LLM, conf=0.78)

  cites [144] sourceExperimental — accuracy not yet measured

In the paper

“Appreciably, the pharmacology of the first-generation of such unimolecular triagonists already proved superior to any best-in-class single, or co-agonist peptides at that time150-154 (Figure 2).”

What the sources say

• ?Not checked — no full text of the sourcecites [150] source
• ?Not checked — no full text of the sourcecites [151] source
• ?Not checked — no full text of the sourcecites [152] source
• ?Could not verify

  Our copy does not address first-generation unimolecular triagonists or compare them with best-in-class single and co-agonist peptides. The section “Is It at All Possible to Reconcile the Two Viewpoints?” instead compares two GIP–GLP-1 dual agonists with individual GLP-1 agonists; searches for triagonists and triple agonists found no decisive passage. (LLM, conf=0.74)

  cites [153] sourceExperimental — accuracy not yet measured
• ?Could not verify

  The Introduction and Discussion discuss tirzepatide, a dual GIP/GLP-1 receptor agonist, and compare it with GLP-1 receptor agonist monotherapy. A search for first-generation unimolecular triagonists and comparisons with single or co-agonist peptides found no passage addressing the claimed superiority. (LLM, conf=0.76)

  cites [154] sourceExperimental — accuracy not yet measured

In the paper

“moreover, when compared with a GLP-1R/GCGR co-agonist, this effect was primarily ascribed to an increase in energy expenditure153.”

What the sources say

• ?Could not verify

  The discussion in “Is It at All Possible to Reconcile the Two Viewpoints?” describes weight loss with GIP–GLP-1 co-agonists, but does not discuss SAR441255 or the claimed comparison. Searches for SAR441255 and energy expenditure found no passage attributing its weight-loss effect primarily to increased energy expenditure relative to a GLP-1R/GCGR co-agonist; energy expenditure appears in reference titles, not as this finding. (LLM, conf=0.76)

  cites [153] sourceExperimental — accuracy not yet measured

In the paper

“Comparable weight loss with tirzepatide was achieved after four weekly doses155.”

What the sources say

• Partly supported

  The Introduction reports weight loss with tirzepatide in a 26-week trial and says its properties enable once-weekly dosing. The Discussion describes weight-control efficacy comparable to semaglutide, but no passage found reports comparable weight loss after four weekly doses. (LLM, conf=0.85)

  cites [155] sourceExperimental — accuracy not yet measured

In the paper

“In lean cynomolgus non-human primates, positron emission tomography imaging revealed high receptor occupancy to GLP-1R and GCGR153.”

What the sources say

• ?Could not verify

  The passages from the paper’s References and the passage discussing obese nonhuman primates do not address receptor-occupancy imaging in lean cynomolgus primates. Searches for SAR441255 and PET receptor occupancy found no passage reporting the claimed GLP-1R and GCGR result. (LLM, conf=0.76)

  cites [153] sourceExperimental — accuracy not yet measured

In the paper

“Similar superior metabolic outcomes were also observed in obese diabetic cynomolgus non-human primates153.”

What the sources say

• ?Could not verify

  The Abstract reports reduced weight gain in obese nonhuman primates given a GIP-receptor antagonist, but does not identify SAR441255, diabetic cynomolgus primates, or superior metabolic outcomes for that compound. Searches for SAR441255 and cynomolgus primates found no passage addressing the attributed result. (LLM, conf=0.78)

  cites [153] sourceExperimental — accuracy not yet measured

In the paper

“In a Phase 1 study, the addition of GIPR activity to GLP-1R/GCGR co-agonism was reported to greatly potentiate the weight-lowering and glycemic efficacy in overweight subjects (NCT04521738)153.”

What the sources say

• Partly supported

  The Abstract (page not provided) reports substantial weight loss and improved glycated hemoglobin in overweight patients with type 2 diabetes treated with the dual GIP–GLP-1 agonist tirzepatide in a Phase 2 study. It does not report a Phase 1 study, addition of GIPR activity to GLP-1R/GCGR co-agonism, or results for NCT04521738. (LLM, conf=0.86)

  cites [153] sourceExperimental — accuracy not yet measured

In the paper

“2) GCGR agonism stimulates in increase in energy expenditure151,155”

What the sources say

• ?Not checked — no full text of the sourcecites [151] source
• ?Could not verify

  The Discussion addresses GIPR and GLP-1R signaling and mentions glucagon-receptor tracers, but does not link GCGR agonism to energy expenditure. A search for “energy expenditure” found the term only in a reference title about GIP, not in a finding about GCGR agonism. No passage in our copy establishes the attributed claim. (LLM, conf=0.74)

  cites [155] sourceExperimental — accuracy not yet measured

In the paper

“For instance, GIPR agonism within multi-receptor agonists, improves bone metabolism153.”

What the sources say

• Partly supported

  The passage labeled Abstract (page unavailable) reports that GIP infusions in humans reduce bone resorption, apparently through GIP receptors on bone cells. It does not establish that GIPR agonism within multi-receptor agonists improves bone metabolism; the co-agonist passages discuss weight and glucose outcomes instead. (LLM, conf=0.86)

  cites [153] sourceExperimental — accuracy not yet measured

In the paper

“In conclusion, bariatric surgery still stands as the benchmark for weight loss, triggering weight reduction of ~25-30% within a 1-2 year period175.”

What the sources say

• ?Could not verify

  The Results describe tirzepatide-related weight loss in mice and rats over days or weeks, not outcomes after bariatric surgery. Searches for bariatric surgery, a 25–30% reduction, and a 1–2-year period found no passage in our copy addressing the claim. Page numbers were not available. (LLM, conf=0.76)

  cites [175] sourceExperimental — accuracy not yet measured

In the paper

“The physiological role of GIP in other endocrine functions, such as the maintenance of bone health, is one of appreciable importance173.”

What the sources say

• ?Could not verify

  The Main section describes tirzepatide’s GIP and GLP-1 receptor activity in relation to appetite, energy intake and metabolic function, but does not address GIP’s role in bone health. Searches for “maintenance of bone health” and “GIP bone endocrine function” found no passage in our copy supporting that point; page numbers were not available. (LLM, conf=0.76)

  cites [173] sourceExperimental — accuracy not yet measured

In the paper

“Considering the prominent role of adipose tissue in energy homeostasis59,172, it is plausible that GIPR agonism in fat could harness beneficial effects on metabolic homeostasis.”

What the sources say

• ?Could not verify

  The citation is attached to the statement about adipose tissue’s prominent role in energy homeostasis. The paper’s Discussion addresses GLP-1 effects on pancreatic hormone secretion and glucose turnover, but the passages found when searching for adipose tissue, energy homeostasis, fat, and GIPR agonism do not address that role. (LLM, conf=0.73)

  cites [59] sourceExperimental — accuracy not yet measured
• ?Could not verify

  The citation is attached to the statement about adipose tissue’s role in energy homeostasis, rather than to the citing authors’ subsequent speculation. The Introduction (page not available) discusses obesity and metabolic effects of GIP and GLP-1, and the Discussion (page not available) considers possible mechanisms of tirzepatide, but neither addresses adipose tissue’s role in energy homeostasis. Searches for adipose tissue and fat did not find a passage establishing that point. (LLM, conf=0.72)

  cites [172] sourceExperimental — accuracy not yet measured

In the paper

“With respect to GIPR agonism, while a definitive mechanism in how GIPR signaling impacts energy balance is yet to be reported, GIPR activation has been associated with improved adipose tissue health41,106,123,171.”

What the sources say

• ?Not checked — no full text of the sourcecites [41] source
• ?Could not verify

  The Results section on hepatic FXR reports that GCGR agonism reduced adipocyte size and brown-adipose lipid infiltration; it does not attribute those effects to GIPR activation. A separate Results passage reports decreased circulating GIP after treatment, but does not assess GIPR signaling or its effect on adipose tissue health. Searches for GIPR activation and the GIP receptor found no passage addressing the claim. (LLM, conf=0.76)

  cites [106] sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [123]

In the paper

“Collectively, this supports the prospect that GCGR agonism may be employed as a viable option for the treatment of metabolic diseases associated with obesity, particularly when used in adjunct to therapeutics that are capable of restraining glucagon’s acute glycemic and cardiovascular limitations.”

In the paper

“In particular, preclinical studies have revealed that glucagon may be harnessed for metabolic benefits, such as body weight loss in the context of obesity18.”

What the sources say

• ?Not checked — no full text of the sourcecites [18] source

In the paper

“and while GIP-mediated weight loss is fully preserved in Glp1r-deficient mice45,49”

What the sources say

• ?Not checked — no full text of the sourcecites [45] source
• ?Not checked — no full text of the sourcecites [49] source

In the paper

“GIP exerts a significant role in adipose tissue blood flow35, and under conditions of hyperinsulinemia, promotes lipid deposition in adipocytes by stimulating lipoprotein lipase36,37.”

What the sources say

• ?Not checked — no full text of the sourcecites [35] source
• ?Not checked — no full text of the sourcecites [36] source
• ?Not checked — no full text of the sourcecites [37] source

In the paper

“Preclinical studies further revealed that chemogenetic activation of GIPR neurons in either the hypothalamus or the hindbrain reduces food intake42,43 (Figure 1)”

What the sources say

• ?Not checked — no full text of the sourcecites [42] source
• ?Not checked — no full text of the sourcecites [43] source

In the paper

“In fact, GIP-driven weight loss is synergistically enhanced by adjunct GLP-1R agonism47-49”

What the sources say

• ?Not checked — no full text of the sourcecites [47] source
• ?Not checked — no full text of the sourcecites [48] source
• ?Not checked — no full text of the sourcecites [49] source

In the paper

“The peptide is notably more potent at GLP-1R, relative to GCGR, with a ratio of ~5:192.”

What the sources say

• ?Not checked — no full text of the sourcecites [92] source

In the paper

“Interestingly, treatment of diet-induced obese mice with a GCGR agonist revealed that glucagon-stimulated energy expenditure and weight loss can also be driven by hepatic amino acid catabolism, and thus a systemic response to hypoaminoacidemia74”

What the sources say

• ?Not checked — no full text of the sourcecites [74] source

In the paper

“Nevertheless, these results highlight the precedent-setting ability of GLP-1R agonists, when properly dose-titrated, to meaningfully reduce body weight.”

In the paper

“Particularly in subjects with obesity and persistent T2D, GLP-1R-driven weight loss still plateaus in the single digit range69”

What the sources say

• ?Not checked — no full text of the sourcecites [69] source

In the paper

“A recent Phase 2 study, comprising 248 overweight and obese Chinese subjects, documented a body weight reduction of ~11.3% from baseline following 24 weeks of mazdutide treatment at the highest dose89.”

What the sources say

• ?Not checked — no full text of the sourcecites [89] source

In the paper

“Consequentially, a pharmacotherapy that engages multiple key metabolic signals would be expected to achieve greater weight loss, relative to a drug that targets only one metabolically relevant signaling pathway.”

In the paper

“In contrast, semaglutide was less efficacious in subjects with obesity and T2D, with placebo-corrected weight loss of only 6.2% reported with 68 weeks of treatment69.”

What the sources say

• ?Not checked — no full text of the sourcecites [69] source

In the paper

“However, the pharmacological use of native bioactive GLP-1 is limited by an exceedingly short half-life (~2-3 min), resulting from rapid renal elimination and proteolytic degradation by dipeptidyl peptidase-4 (DPP-4)61 and neutral endopeptidase 24.1162.”

What the sources say

• ?Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  cites [61]
• ?Not checked — no full text of the sourcecites [62]

In the paper

“Together with an appreciable (~50%) sequence homology with the incretin hormones76”

What the sources say

• ?Not checked — no full text of the sourcecites [76] source

In the paper

“This indicates that some of the cardiorenal benefits observed for co-agonists may exert their beneficial effects directly through a kidney-GCGR signaling axis.”

In the paper

“Taken together, cotadutide and similar co-agonists, are firmly positioned as viable prospects for the treatment of MASLD and MASH.”

In the paper

“Following 68 weeks of treatment, semaglutide impressively lowered body weight in non-diabetic, obese individuals by 14.9%, relative to 2.4% in placebo-treated controls68.”

What the sources say

• ?Not checked — no full text of the sourcecites [68] source

In the paper

“Unimolecular multi-receptor agonists that employ several independent signaling pathways are emerging as the best-in-class drugs for glycemic control and weight loss.”

In the paper

“Moreover, their metabolic benefits signal that enhanced glucagon agonism can promote hepatic de-lipidation, which should have vast medicinal advantages for the treatment of obesity, independent of the magnitude of weight loss.”

In the paper

“In 2013, ahead of the curve of multi-receptor drug discovery for the treatment of obesity, the first GLP-1R/GIPR co-agonist was generated, as a single peptide with potent, balanced co-agonism at GLP-1R and GIPR48.”

What the sources say

• ?Not checked — no full text of the sourcecites [48] source

In the paper

“near-normalization of hyperglycemia restores the insulinotropic effect of GIP in subjects with T2D116.”

What the sources say

• ?Not checked — no full text of the sourcecites [116] source

In the paper

“Taken together, these pioneering preclinical studies established GLP-1R/GIPR co-agonism as an encouraging pharmacological strategy to promote weight loss beyond what can be achieved with GLP-1R agonism alone”

In the paper

“In diet-induced obese mice, the co-agonist impressively reduced body weight by ~26.9%, compared to 15.6% following liraglutide treatment.”

What the sources say

• ?Not checked — no full text of the sourcecites [48] source

In the paper

“However, after completion of Phase 2b trials, in which a single tested dose displayed only moderate superiority on body weight and glucose control over liraglutide after 12 weeks of treatment in subjects with T2D126, the clinical development of MAR709 was discontinued in favor of proceeding with the clinical advancement of the GLP-1R agonist, semaglutide.”

What the sources say

• ?Not checked — no full text of the sourcecites [126] source

In the paper

“the insulinotropic action of GIP is largely dampened in subjects with T2D104”

What the sources say

• ?Not checked — no full text of the sourcecites [104] source

In the paper

“In a Phase 1 study comprising of 100 overweight and obese subjects, 12 weeks of treatment with pemvidutide (1.8 mg) resulted in placebo-corrected weight loss of ~10.3% (NCT04561245).”

What the sources say

• ?Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  cites NCT04561245

In the paper

“These studies essentially identified the brain GIP system as a new regulator of energy metabolism.”

In the paper

“the success of GLP-1R/GIPR co-agonism, as discussed below, has rehabilitated the opinion that GIPR agonism is a successful constituent of incretin-based therapies.”

In the paper

“The second important GLP-1R/GIPR co-agonist generated was LY3298176, also termed tirzepatide47.”

What the sources say

• ?Not checked — no full text of the sourcecites [47] source

In the paper

“The SURPASS J-mono trial evaluated the glycemic effects of tirzepatide in Japanese subjects with T2D; demonstrating that after 52 weeks of treatment, HbA1c levels were lowered by −2.8%, relative to −1.3% in subjects receiving dulaglutide138.”

What the sources say

• ?Not checked — no full text of the sourcecites [138] source

In the paper

“Collectively, it is apparent that GLP-1R/GIPR co-agonists have firmly established an unprecedented benchmark for medicinal drugs aiming to treat T2D and obesity.”

In the paper

“GIPR agonism has been preclinically characterized to amplify the glycemic and weight-lowering performance of GLP-1R/GIPR co-agonism, when compared with selective GLP-1R agonism45-46”

What the sources say

• ?Not checked — no full text of the sourcecites [45] source
• ?Not checked — no full text of the sourcecites [46] source

In the paper

“and as such, should be credited as an essential component that helps achieve the optimal metabolic benefits of the co-agonist.”

In the paper

“a highly desirable property that may contribute to increased tolerability of the GIP-based drugs relative to GLP-1-based monotherapies at higher doses.”

In the paper

“Similar impressive improvements in glycemia were reported from the SURPASS J-combo trial, in which tirzepatide was administered for 52 weeks as add-on therapy to sulfonylureas, biguanides, α-glucosidase inhibitors, thiazolidinediones, glinides, or sodium-glucose transport protein 2 (SGLT2) inhibitors in Japanese subjects with poorly-controlled T2D139.”

What the sources say

• ?Not checked — no full text of the sourcecites [139] source

In the paper

“In diet-induced obese mice, MAR423 displayed impressive dose-dependent body weight-lowering effects of 26.6% in 20 days, compared to 15.7% with GLP-1R/GIPR co-agonist treatment.”

What the sources say

• ?Not checked — no full text of the sourcecites [150] source

In the paper

“Taken together, it is now evident that by partnering GLP-1R and GIPR to generate incretin-based co-agonists, achieves spectacular metabolic outcomes with enhanced therapeutic dosing.”

In the paper

“It is the current benchmark for the greatest weight loss ever reported with this class of anti-obesity drug candidates.”

In the paper

“The clinical results regarding tirzepatide appear to anchor GIPR activity as much as GLP-1 activity in the treatment of obesity.”

In the paper

“In other words, there is a high rate of “recidivism” similar to what is observed in lifestyle intervention trials.”

In the paper

“These results thus highlight the tremendous potential for triagonist peptides to treat obesity-associated MASLD.”

In the paper

“A recent report also puts forth potent reno-protective effects that are exerted through the GCGR in the kidney75.”

What the sources say

• ?Not checked — no full text of the sourcecites [75] source

In the paper

“More recently, in a Phase 2 trial, retatrutide achieved a stunning record of ~24.2% placebo-corrected weight loss in obese subjects without T2D after 48 weeks of treatment164 (Table 2).”

What the sources say

• ?Not checked — no full text of the sourcecites [164] source

In the paper

“Retatrutide further induced dose-dependent weight loss of −8.65 kg from baseline at the highest dose163 (Table 2).”

What the sources say

• ?Not checked — no full text of the sourcecites [163] source

In the paper

“Nonetheless, the deepened appreciation for the role that glucagon has on energy expenditure has placed this hormone in a new light, and rekindled its consideration as a component that could provide additional weight loss when needed, or to sustain the weight loss that may otherwise wane through some form of supplementation70.”

What the sources say

• ?Not checked — no full text of the sourcecites [70] source

In the paper

“Notably, the LY3437943 triagonist peptide outperformed the GLP-1R/GIPR co-agonist tirzepatide to achieve a greater degree of weight loss47;”

What the sources say

• ?Not checked — no full text of the sourcecites [47] source

In the paper

“Consistent with these findings, a triple separate physical mixture of GLP-1R, GIPR and GIPR mono-agonists also served to dampen hepatic triglyceride accumulation in a mouse model of MASLD and fibrosis157.”

What the sources say

• ?Not checked — no full text of the sourcecites [157] source

In the paper

“Indeed, discontinuation of either semaglutide168,169 or tirzepatide170 leads to a significant rebound in body weight gain.”

What the sources say

• ?Not checked — no full text of the sourcecites [168] source
• ?Not checked — no full text of the sourcecites [169] source
• ?Not checked — no full text of the sourcecites [170] source

In the paper

“In the SURMOUNT-4 trial, obese subjects that were treated with tirzepatide for 36 weeks exhibited a reduction in body weight of ~21%170.”

What the sources say

• ?Not checked — no full text of the sourcecites [170] source

In the paper

“Collectively, preclinical studies identified that unimolecular triagonist peptides are vastly superior to existing co-agonists and mono-agonists in the regulation of body weight, satiety, hepatic lipid metabolism and glycemic control (Figure 2).”

In the paper

“Taken together, this is a sober realization that novel weight loss pharmacotherapies, despite their unprecedented effectiveness, may not be regarded as the ultimate cure for obesity.”

In the paper

“which suggested that the peptide has the potential to resolve MASLD.”

In the paper

“Despite this weight regain, the subjects that were administered placebo still maintained a ~10% weight loss compared to their starting body weight, which is highly meaningful.”

What the sources say

• ?Not checked — no full text of the sourcecites [170] source

In the paper

“as HM15211 specifically displays much potential in obesity-related liver disease, as a point of distinction for the more customary focus on glucose control and body weight-lowering capabilities.”

In the paper

“Following 12 weeks of treatment, retatrutide reduced absolute HbA1c levels by −1.90%, compared to −0.96% and −0.34% with dulaglutide or placebo, respectively163.”

What the sources say

• ?Not checked — no full text of the sourcecites [163] source

In the paper

“While this notion is generally true, there is recent evidence to suggest that some degree of the initial weight loss may be retained following a wash-out period of the drug.”

In the paper

“Shortly thereafter, the clinical performance of semaglutide in the treatment of T2D and/or obesity was substantially eclipsed by the integrated pharmacology of GIP and GLP-1, in tirzepatide.”

In the paper

“As such, the unintended prospect that inhibiting GIP activity in a T2D patient population with reduced bone mineral density, could represent a chronic adverse risk that needs to be addressed.”

In the paper

“The serendipitous step forward emerged when semaglutide, a peptide designed for increased patient convenience in reducing injectable dosing from daily to once weekly, proved doubly efficacious in lowering body weight to beyond 10%, when compared with a daily dosing of the chemically related peptide, liraglutide.”

In the paper

“The peptide served to double the conviction for the prospect of body weight-lowering efficacy comparable to bariatric surgery; a goal that was within reach, for the first time, through the use of multi-mechanism pharmacology.”

In the paper

“Nevertheless, at present, this suggests that to reap the full benefits of weight loss, lifelong drug exposure may be required.”

In the paper

“Preclinical results and emerging clinical data with triple agonism indicate further advances.”